Navigation Links
Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
Date:8/13/2009

VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced that it has received approval to begin marketing the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM), Polypropylene and Nylon product lines in Brazil.

"We are very excited about the approval of the Quill SRS product lines in Brazil, one of the largest surgical markets in the world. Quill has been lauded in the U.S., Europe and Canada for the efficiency it brings to wound closure. Now, Brazilian patients and surgeons in plastics, orthopedics and gynecology can benefit from it as well," said Dr. William Hunter, President and CEO of Angiotech.

The Quill SRS product lines include two absorbable sutures - MONODERM and PDO, and two non-absorbable sutures - Polypropylene and Nylon, and are approved for sale in the U.S., Europe, and Canada.

About the Quill(TM) Self-Retaining System (SRS)

Quill SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill SRS distribute tension across the wound and eliminate the need for knots.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Ca
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Research and Markets has announced the addition ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... genetic material or genomes of an organism. It is ... and development of diagnostic and therapeutic solutions for a ... supported by three major product segments: Instruments, Consumables, and ...
(Date:7/31/2014)... San Francisco, Calif. (PRWEB) July 31, 2014 ... provides newly diagnosed patients with an overview of the ... the management of drug side effects, as well as ... , “We’re grateful to Dr. Sandy Srinivas for organizing ... 25-year survivor of kidney cancer. “Sandy and her colleagues ...
(Date:7/31/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues, today announced ... will be released on Thursday, August 7, 2014, and ... live webcast at 4:30 p.m. ET that afternoon. Management ...
(Date:7/30/2014)... 2014 Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended June 30, 2014 on Wednesday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its second quarter ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... the promotions of Linda Arterburn, PhD, Francisco Leon, MD, ... "We are pleased,to announce the promotions of several of ... a fine group of talented people working here to ... with celiac,disease, asthma, eye disorders, and other areas to ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
... OF PHASE II DATA FOR LEAD DRUG CANDIDATE ... Oct. 2 Transave, Inc., a,biopharmaceutical company focused ... of serious lung diseases,today announced that it has ... and Compass Horizon Funding Company LLC, an affiliate ...
Cached Biology Technology:Alba Therapeutics Corporation Announces Promotions 2Alba Therapeutics Corporation Announces Promotions 3Alba Therapeutics Corporation Announces Promotions 4DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5
(Date:7/31/2014)... the brain processes speech, potentially increasing the difficulty ... The University of Texas at Dallas. , In ... and Hearing , researchers demonstrated for the first ... recognition of speech sounds. , Noise-induced hearing loss ... an estimated 15 percent of Americans between the ...
(Date:7/31/2014)... identify and treat those with fibromuscular dysplasia (FMD). FMD ... arteries in the body, which can restrict blood flow to ... report appearing in August 2014 issue of The ... may not be limited to the arteries as currently believed. ... and joints, as well as evidence that inflammation may be ...
(Date:7/31/2014)... the Rim Fire was in full fury, raging swiftly ... entered the backcountry of Yosemite National Park in California,s ... park, the battle began to turn, enacting a case ... combine to fuel large, severe fires. , "When the ... where fire had been used as a management tool, ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... will present the 2013 William Dameshek Prize to Andrew S. ... research on the cellular and molecular causes of blood clots. ... MD, a renowned hematologist, past president of ASH, and the ... an individual who has made a recent, outstanding contribution to ...
... known as important sources of energy for all organisms. ... certain types of sugars, known as polysaccharides, may also control ... produce hard structures such as shells and exoskeletons of mollusks, ... of the National Academy of Sciences , Anthony Giuffre, a ...
... is killing you, you may be right, but what you ... even before you were born. In a new report appearing ... Journal , Harvard researchers find that epigenetic disruptions, which ... common at birth. Possibly, these aberrations result from stressors in ...
Cached Biology News:The American Society of Hematology honors Andrew S. Weyrich, Ph.D., with 2013 William Dameshek Prize 2Geoscientists unearth mineral-making secrets potentially useful for new technologies 2Geoscientists unearth mineral-making secrets potentially useful for new technologies 3Fetal stress disrupts the way genes are transmitted 2
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: